MARKET

ALNA

ALNA

Allena Pharmaceu
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.1270
-0.0009
-0.70%
Pre Market: 0.1299 +0.0029 +2.28% 06:20 08/11 EDT
OPEN
0.1307
PREV CLOSE
0.1279
HIGH
0.1330
LOW
0.1238
VOLUME
14.58K
TURNOVER
--
52 WEEK HIGH
1.170
52 WEEK LOW
0.0683
MARKET CAP
13.68M
P/E (TTM)
-0.1909
1D
5D
1M
3M
1Y
5Y
First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment
Allena Pharmaceuticals (NASDAQ:ALNA) on Tuesday <a h...
Seekingalpha · 07/19 14:01
Allena Pharmaceuticals Announces Completion Of Enrollment Of Cohorts A And B Of ALLN-346 Phase 2a Study 202 In Patients With Gout And Stages 2 And 3 Chronic Kidney Disease
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) ("Allena" or the "Company"), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class,
Benzinga · 07/19 12:01
Allena Pharmaceuticals Says Enrollment Complete in Two Cohorts of Gout, Chronic Kidney Disease Treatment Study
MT Newswires · 07/19 09:26
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 07/14 12:16
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Investor Place · 07/14 11:28
BRIEF-Allena Pharma Reports New Meeting Date, Record Date For Special Meeting To Approve Reverse Stock Split
BRIEF-Allena Pharma Reports New Meeting Date, Record Date For Special Meeting To Approve Reverse Stock Split
Reuters · 07/12 20:12
Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split
NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and sever...
GlobeNewswire · 07/12 20:05
BRIEF-Allena Pharmaceuticals Says May Offer, Sell Shares Of Common Stock Of Up To $6.2 Million
BRIEF-Allena Pharmaceuticals Says May Offer, Sell Shares Of Common Stock Of Up To $6.2 Million
Reuters · 07/11 13:25
More
No Data
Learn about the latest financial forecast of ALNA. Analyze the recent business situations of Allena Pharmaceu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALNA stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
High4.000
Average4.000
Low4.000
Current 0.1270
EPS
Actual
Estimate
-0.19-0.14-0.10-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 64
Institutional Holdings: 10.37M
% Owned: 9.63%
Shares Outstanding: 107.73M
TypeInstitutionsShares
Increased
6
77.97K
New
4
29.80K
Decreased
10
3.74M
Sold Out
6
5.32M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Chairman/Co-Founder/Director
Alexey Margolin
President/Chief Executive Officer/Director
Louis Brenner
Chief Financial Officer
Richard Katz
Chief Operating Officer/Senior Vice President
Geoffrey Swire
Other
David Clark
Independent Director
Allene Diaz
Independent Director
Mark Fitzpatrick
Independent Director
Ann Miller
Independent Director
Gino Santini
No Data
No Data
About ALNA
Allena Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The Company is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The Company’s lead product candidate, reloxaliase, is an oral enzyme therapeutic developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate (UOx) levels and commonly associated with kidney stones, CKD and ESRD. Its second product candidate, ALLN-346, is an orally administered, novel, urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD. The Company is conducting two Phase IIa studies for ALLN-346.

Webull offers kinds of Allena Pharmaceuticals Inc stock information, including NASDAQ:ALNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALNA stock methods without spending real money on the virtual paper trading platform.